Citi Reiterates Buy on Lincare Holdings, Reduces PT to $35

Citi reiterated its Buy rating on Lincare Holdings LNCR. At the same time, the rating agency reduced its price target on the company's stock from $41 to $35. On Monday, LNCR closed the day at $28.49. Its shares had a difficult session in today's pre-market trading, losing 6.11% of their value to trade around $26.75.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Price TargetReiterationAnalyst RatingsCitiHealth CareHealth Care Services
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!